

Time to stop using ineffective Covid-19 drugs

Salim S. Abdool Karim and Nikita Devnarain

Supplementary online Table 1: World Health Organisation recommendations on which medications should or should not be used to treat Covid-19 (adapted from the WHO living guidelines for therapeutics and Covid-19, 14 July 2022)⁸

	Strong recommendation against	Recommendation against	No recommendation for or against	Recommendation for	Strong recommendation for
Non-severe disease	<ul style="list-style-type: none"> • Convalescent plasma • Hydroxychloroquine • Lopinavir-ritonavir • Colchicine 	<ul style="list-style-type: none"> • Corticosteroids^a • Ivermectin^b • Fluvoxamine^b • Nirmatrelvir and ritonavir^{a,c} 	<ul style="list-style-type: none"> • Heparin • Metformin 	<ul style="list-style-type: none"> • Molnupiravir^{a,d} • Sotrovimab^{a,d,e} • Remdesivir^{a,d} • Casirivimab and imdevimab^{a,d,f} 	<ul style="list-style-type: none"> • Nirmatrelvir and ritonavir^d
Severe disease	<ul style="list-style-type: none"> • Hydroxychloroquine • Lopinavir-ritonavir 	<ul style="list-style-type: none"> • Ruxolitinib and tofacitinib^a • Ivermectin^b • Convalescent plasma^b 		<ul style="list-style-type: none"> • Casirivimab and imdevimab^{a,f} 	<ul style="list-style-type: none"> • Corticosteroids • IL-6 receptor blockers or Baricitinib

Note: Severe disease is defined as oxygen saturation <90% on room air, pneumonia or respiratory distress

^a Conditional recommendation

^b Only recommended for use within the context of a clinical trial

^c In non-severe patients at low risk of hospitalization

^d In non-severe patients at highest risk of hospitalization

^e Excluding pregnant or breastfeeding women, and children

^f If seronegative for SARS-CoV-2 antibodies (note: evidence of limited efficacy for omicron BA.1 variant)

⁸Agarwal A, Rochweg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. *BMJ*. 2020;370:m3379.